Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
LIMBER
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
- NCT04279847 ↗
- Active, not recruiting
- Incyte Corporation
- Focused
We haven't built an HCP commentary report on LIMBER yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LIMBER so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Myelofibrosis; Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome; Myeloproliferative Neoplasm; Relapsed or Refractory Primary Myelofibrosis; Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis); ET (Essential Thrombocythemia)
- Interventions
- INCB057643; Ruxolitinib
- Arms
- Part 1 : INCB057643 Monotherapy · Experimental
- Part 2 : INCB057643 Combination with Ruxolitinib · Experimental
- Enrollment
- 140
- Primary outcomes
- Number of treatment-emergent adverse events
- Sponsor
- Incyte Corporation
- Start
- Feb 23, 2021
- Primary completion
- Apr 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04279847 · updated Apr 1, 2026